the goal of this observational study is to the find the molecular mechanisms underlying the prognosis process of Retinal vein occlusion in patients with retinal vein occlusion . The main question it aims to answer is:
What are the changes in protein in the aqueous humor during treatment in patients who are sensitive to anti-VEGF drug therapy?
Eligibility
Sex
ALL
Min age
20 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Cystic or diffuse edema in the macular area, retinal vein tortuous dilation with hemorrhage
* Optical coherence tomography (OCT) examination showed that the macular area was raised, edema and thickened
* Monocular disease, baseline central retinal thickness (CRT) ≥ 250mm
* Intravitreal injection, laser photocoagulation and blood circulation and blood stasis removal drugs were not treated before surgery
* The patient had normal blood pressure, negative urine protein, normal liver and kidney function, and normal electrocardiogram
Exclusion Criteria:
* Patients with fluorescein fundus angiography (FFA) showing a large area (10 optic disc areas) without perfusion requiring retinal photocoagulation
* Patients with chronic dacryocystitis, glaucoma, cataract, severe proliferative vitreoretinopathy or vitreous hemorrhage, epi macular membrane or macular ischemia, diabetic retinopathy, age-related macular degeneration, ocular trauma and other diseases
* Intravitreal therapy or laser photocoagulation with corticosteroids or anti-VEGF drugs within three months before the study
Primary outcome measure(s)
Central retinal thickness — March 2023 - June 2024 The Heidelberg Optical Coherence Tomography scanner was used to detect the central retinal thickness in patients
Trial sites (1)
Facility
City
Region
Status
Tianjin medical university eye hospital
Tianjin
Province
More Tianjin Medical University Eye Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.